Human Immunodeficiency Virus (HIV) Infections
Conditions
Brief summary
The primary objective of this study is to evaluate the safety and tolerability of Islatravir (ISL) in trans and gender diverse (TGD) participants who are receiving gender-affirming hormone therapy (GAHT) and are at low-risk for human immunodeficiency virus 1 (HIV-1) infection.
Interventions
DRUGIslatravir
60 mg Islatravir taken orally in tablet form once monthly for up to 24 weeks
Sponsors
Merck Sharp & Dohme LLC
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Is confirmed HIV-uninfected based on negative HIV-1/HIV-2 test result before allocation to study intervention. * Is on stable GAHT and does not intend to change therapy through Week 4 of the study. * Has a low-risk of HIV infection. * Identifies with a gender that is different from that assigned at birth. * A participant assigned female at birth is eligible if not pregnant or chest-feeding and is not of childbearing potential (POCBP) or: Is a POCBP and using an acceptable contraceptive method, or be abstinent from penile-vaginal intercourse with an individual capable of producing sperm (abstinent on a long term and persistent basis); a POCBP must have a negative highly sensitive pregnancy test (\[urine or serum\] as required by local regulations) within 24 hours before the first dose of study intervention; If a urine test cannot be confirmed as negative (e.g, an ambiguous result), a serum pregnancy test is required. In such cases, the participant must be excluded from participation if the serum pregnancy result is positive; the investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a participant assigned female at birth with an early undetected pregnancy; contraceptive use by participant assigned female at birth should be consistent with local regulations.
Exclusion criteria
* Has known current or chronic history of liver disease (e.g, non-alcoholic or alcoholic steatohepatitis) or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome, asymptomatic gallstones, or cholecystectomy), unless the participant has stable liver function tests and no evidence of hepatic synthetic dysfunction. * Has a history of malignancy within 5 years of screening except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or in situ anal cancers. * Has taken cabotegravir, lenacapavir, or any other long-acting HIV prevention product at any time (past or current use). * Is currently participating in or has participated in a clinical study with an investigational compound or device, within 30 days before Day 1 through the duration of the study. * Is expecting to conceive or donate eggs at any time during the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Participants with one or more adverse events (AEs) | Up to 26 weeks | Number of participants with one or more AEs will be reported. |
| Participants with an AE leading to discontinuation of study intervention | Up to 20 weeks | Number of participants with an AE leading to discontinuation of study intervention will be reported. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Area Under the Curve (AUC) of plasma islatravir (ISL) | Pre-dose on Day 1; any time on Weeks 1, 2 and 3; pre-dose on Weeks 4, 8, 12, 16, 20; any time on Week 24 | Area Under the Curve from time 0 to 672 hours post-dose (AUC0-672hr) of plasma islatravir (ISL) will be reported. |
| Maximum concentration (Cmax) of plasma ISL | Pre-dose on Day 1; any time on Weeks 1, 2 and 3; pre-dose on Weeks 4, 8, 12, 16, 20; any time on Week 24 | Maximum concentration (Cmax) of plasma ISL will be reported. |
| Trough concentration (Ctrough) of plasma ISL | Pre-dose on Day 1; any time on Weeks 1, 2 and 3; pre-dose on Weeks 4, 8, 12, 16, 20; any time on Week 24 | Trough concentration (Ctrough) of plasma ISL will be reported. |
| Apparent terminal half-life (t1/2) of plasma ISL | Pre-dose on Day 1; any time on Weeks 1, 2 and 3; pre-dose on Weeks 4, 8, 12, 16, 20; any time on Week 24 | Apparent terminal half-life (t1/2) of plasma ISL will be reported. |
Outcome results
None listed